Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Axsome Therapeutics Inc before investing.

In this article, we go over a few key elements for understanding Axsome Therapeutics Inc’s stock price such as:

• Axsome Therapeutics Inc’s current stock price and volume
• Why Axsome Therapeutics Inc’s stock price changed recently
• Upgrades and downgrades for AXSM from analysts
• AXSM’s stock price momentum as measured by its relative strength

About Axsome Therapeutics Inc (AXSM)

Before we jump into Axsome Therapeutics Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Want to learn more about Axsome Therapeutics Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Axsome Therapeutics Inc.

Axsome Therapeutics Inc’s Stock Price as of Market Close

As of September 04, 2024, 4:00 PM, CST, Axsome Therapeutics Inc’s stock price was $95.56.

Axsome Therapeutics Inc is up 6.59% from its previous closing price of $89.65.

During the last market session, Axsome Therapeutics Inc’s stock traded between $88.04 and $91.78. Currently, there are 47.57 million shares of Axsome Therapeutics Inc stock available for purchase.

Unfortunately, Axsome Therapeutics Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Axsome Therapeutics Inc Stock Price History

Axsome Therapeutics Inc’s (AXSM) price is currently up 7.54% so far this month.

During the month of September, Axsome Therapeutics Inc’s stock price has reached a high of $96.85 and a low of $88.04.

Over the last year, Axsome Therapeutics Inc has hit prices as high as $98.40 and as low as $55.02. Year to date, Axsome Therapeutics Inc’s stock is up 23.89%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Axsome Therapeutics Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 03, 2024, there were 14 analysts who downgraded Axsome Therapeutics Inc’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Axsome Therapeutics Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Axsome Therapeutics Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Axsome Therapeutics Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Axsome Therapeutics Inc (AXSM) by visiting AAII Stock Evaluator.

Relative Price Strength of Axsome Therapeutics Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 03, 2024, Axsome Therapeutics Inc has a weighted four-quarter relative price strength of 2.34%, which translates to a Momentum Score of 72 and is considered to be Strong.

Want to learn more about how Axsome Therapeutics Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Axsome Therapeutics Inc Stock Price: Bottom Line

As of September 4, 2024, Axsome Therapeutics Inc’s stock price is $95.56, which is up 6.59% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Axsome Therapeutics Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.